Transverse myelitis future or investigational therapies
Jump to navigation
Jump to search
|
Transverse myelitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Transverse myelitis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Transverse myelitis future or investigational therapies |
|
FDA on Transverse myelitis future or investigational therapies |
|
CDC on Transverse myelitis future or investigational therapies |
|
Transverse myelitis future or investigational therapies in the news |
|
Blogs on Transverse myelitis future or investigational therapies |
|
Risk calculators and risk factors for Transverse myelitis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
- No investigational treatment has demonstrated, in an adequately powered confirmatory trial, that it repairs spinal cord injury or improves long-term neurological outcomes in transverse myelitis (TM). The approaches described below should not be presented as routine or guideline-recommended therapy.
- Transverse myelitis is a clinical syndrome with several possible causes. Eligibility for a clinical trial and the biological rationale for an investigational treatment depend on the disease-specific diagnosis, timing of the attack, lesion characteristics, neurological disability, and previous treatment.[1]
- Established acute treatment, rescue treatment, rehabilitation, and disease-specific relapse prevention are addressed in the medical therapy and interventions microchapters and are intentionally not repeated here.
- Enrollment in research must not delay urgent, clinically indicated treatment.
| Clinical bottom line |
|---|
| As of October 2026, an actively registered TM-specific study is evaluating human glial-restricted progenitor-cell transplantation. It remains an early-phase safety study. No regenerative, stem-cell, exosome, or secretome treatment has been established as safe and effective for TM outside a properly regulated clinical trial. |
Future or Investigational Therapies
TM-specific clinical research
| Approach | Study and current status | Evidence-based interpretation |
|---|---|---|
| Human glial-restricted progenitor cells (hGRPs; Q-Cells®) | A ClinicalTrials.gov-registered study, currently listed as recruiting, is a Phase 1/2a, nonrandomized, open-label, sequential-cohort, dose-escalation study with an estimated enrollment of nine adults. It evaluates one-time unilateral surgical transplantation of hGRPs into demyelinated spinal cord lesions in selected patients with chronic, stable idiopathic TM. The primary purpose is to evaluate safety and tolerability; evidence of biological or clinical activity is exploratory.[2] | Q-Cells® are intended to generate astrocytes and oligodendrocytes that might support axons and promote remyelination. Although this mechanism is biologically plausible, no confirmatory human efficacy result has been published or posted. Trial authorization and registry listing do not constitute regulatory approval or evidence of clinical benefit.[3] |
| Long-term follow-up after Q-Cells® transplantation | An observational, invitation-only, long-term follow-up study is designed to monitor recipients of Q-Cells® for up to 10 years.[4] | This is a long-term safety and activity follow-up study, not a separate therapeutic trial. Its existence does not establish treatment efficacy. |
| Adjunctive intravenous immunoglobulin (IVIG) during an acute attack | The United Kingdom multicentre study formally titled A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE) was designed to compare intravenous methylprednisolone (IVMP) plus IVIG with IVMP alone. Only two of the planned 170 participants were randomized; therefore, treatment efficacy and cost-effectiveness could not be determined.[5] | IVIG is not a regenerative therapy and may be used in selected clinical circumstances; however, its incremental benefit as an adjunctive treatment for acute TM remains unconfirmed. Because STRIVE was markedly under-recruited, it does not establish either efficacy or lack of efficacy. An adequately powered trial would be required. |
| Dalfampridine extended-release (D-ER) for chronic walking impairment | A randomized, double-blind, placebo-controlled crossover study enrolled 16 adults with monophasic TM, of whom 13 completed the trial. The difference in the primary walking outcome was not statistically significant. Four participants met the responder definition while receiving D-ER, compared with one participant while receiving placebo (p = 0.33).[6] | This was a small exploratory study of symptomatic walking improvement, not spinal-cord repair or disease modification. The findings are insufficient to establish TM-specific efficacy. Larger confirmatory trials would be required. |
Regenerative products without established TM efficacy
- Commercially offered mesenchymal stromal cells, adipose-derived cells, umbilical-cord products, exosomes, secretomes, and other products marketed as “stem-cell therapy” have not been established as safe and effective treatments for TM in adequately controlled trials.
- The United States Food and Drug Administration (FDA) states that regenerative medicine products requiring approval must undergo FDA oversight in a clinical trial before approval. The FDA has received reports of infections, tumors, neurological events, unwanted inflammatory or immune reactions, and other serious harms following the use of unapproved products. Listing a study on ClinicalTrials.gov does not mean that the product is approved or legally marketed.[7]
- The European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) warned in 2025 that unregulated advanced therapy medicinal products (ATMPs), including cell- and tissue-based products, may cause serious adverse effects without proven benefit. Within the European Union, these products should be supplied only when authorized, used in an authorized clinical trial, or provided under an applicable national hospital exemption.[8]
- The International Society for Stem Cell Research (ISSCR) Guidelines for Stem Cell Research and Clinical Translation require scientific rigor, independent oversight, transparency, appropriate informed consent, and evidence-based clinical translation. The August 2025 update retained the clinical-translation recommendations published in 2021.[9]
Clinical-trial referral considerations
| Step | Clinical consideration |
|---|---|
| Confirm the diagnosis and cause | Reassess whether the patient has idiopathic monophasic TM or an identified infectious, systemic inflammatory, antibody-associated, vascular, compressive, metabolic, neoplastic, or other cause. Results from a study enrolling patients with idiopathic TM must not be generalized to every inflammatory myelopathy.[1] |
| Verify the current registry record | Confirm the recruitment status, study phase, location, eligibility criteria, sponsor, intervention, primary outcome, and contact information directly through the official trial registry because these details may change. |
| Explain the purpose of the study phase | Early-phase studies primarily evaluate safety, tolerability, dose, and feasibility. Participation does not guarantee clinical benefit. |
| Review procedure-specific risks | For intramedullary cell transplantation, discuss the potential risks of laminectomy, spinal-cord injection, perioperative complications, rejection, required immunosuppression, infection, abnormal tissue growth, and the need for long-term surveillance.[2][9] |
| Verify regulatory and ethical oversight | Confirm regulatory authorization, independent research-ethics approval, appropriately qualified investigators, compliant cell manufacturing, adverse-event monitoring, transparent reporting, and a credible long-term follow-up plan.[7][8][9] |
| Do not delay established care | Research enrollment must not postpone acute anti-inflammatory treatment, rescue treatment, treatment of an identified cause, prevention of further attacks when indicated, or rehabilitation. |
References
- ↑ 1.0 1.1 Tisavipat N, Flanagan EP. Current perspectives on the diagnosis and management of acute transverse myelitis. Expert Review of Neurotherapeutics. 2023;23(4):389-411. doi:10.1080/14737175.2023.2195095. PMID: 37026545.
- ↑ 2.0 2.1 ClinicalTrials.gov. Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis. ClinicalTrials.gov identifier: NCT03887273. Sponsor: Q Therapeutics, Inc. Last update posted July 21, 2026. Accessed October 9, 2026.
- ↑ Watts JC, Greenberg B. A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) into Subjects with Transverse Myelitis (TM). Neurology. 2019;92(15 Supplement):P1.2-020. doi:10.1212/WNL.92.15_supplement.P1.2-020.
- ↑ ClinicalTrials.gov. A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells. ClinicalTrials.gov identifier: NCT06163508. Sponsor: University of Texas Southwestern Medical Center. Last update posted April 21, 2026. Accessed October 9, 2026.
- ↑ Absoud M, Brex P, Ciccarelli O, et al. A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). Health Technology Assessment. 2017;21(31):1-50. doi:10.3310/hta21310. PMID: 28639937; PMCID: PMC5512007.
- ↑ Schwartz K, Wymbs NF, Huang H, et al. Randomized, placebo-controlled crossover study of dalfampridine extended-release in transverse myelitis. Multiple Sclerosis Journal—Experimental, Translational and Clinical. 2017;3(4):2055217317740145. doi:10.1177/2055217317740145. PMID: 29270309; PMCID: PMC5731631.
- ↑ 7.0 7.1 United States Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Published June 3, 2021. Accessed October 9, 2026.
- ↑ 8.0 8.1 European Medicines Agency and Heads of Medicines Agencies. Unregulated advanced therapy medicinal products pose serious risks to health. Published March 12, 2025. Accessed October 9, 2026.
- ↑ 9.0 9.1 9.2 International Society for Stem Cell Research. Guidelines for Stem Cell Research and Clinical Translation. Version 1.2. Updated August 2025. Accessed October 9, 2026.